A human monoclonal macroglobulin with specificity for alpha(2----8)- linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA

We have described an IgM antibody from a patient with macroglobulinemia specifically reacting with poly-alpha(2----8)N-acetyl neuraminic acid (NeuNAc) the capsular polysaccharide of two important human pathogens, group B meningococcus and E. coli K1. This antibody has a narrowly defined specificity in its interactions with polysaccharides, being unable to bind poly-alpha(2----9)NeuNAc or alternating poly-alpha(2---- 8)alpha(2----9)NeuNAc. However, it shows interesting crossreactivity with seemingly unrelated polynucleotides and denatured DNA, supporting the hypothesis that charged groups with a given spacing may determine the specificity of antigen-antibody interactions on otherwise dissimilar molecular structures. Despite the crossreactivity with denatured DNA and polynucleotides, the antibody does not appear to have adverse effects in the patient. The antibody protects newborn rats against E. coli K1 infection, as well as the standard horse antiserum H46, and one would expect it to prove useful in humans as an adjunct to antibiotic therapy in infections with group B meningococcus and E. coli K1. We have attempted to clone the antibody-producing cells from peripheral blood, and have shown that the relevant cells are present and can be cultured.

[1]  A. Cross,et al.  Prevention and therapy of experimental Escherichia coli infection with monoclonal antibody , 1985, Infection and immunity.

[2]  F. Ashton,et al.  Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody , 1985, Infection and immunity.

[3]  E. Kabat,et al.  Immunochemical similarities between monoclonal antibacterial Waldenstrom's macroglobulins and monoclonal anti-DNA lupus autoantibodies , 1985, The Journal of experimental medicine.

[4]  R. Schwartz,et al.  Homology of the NH2-terminal amino acid sequences of the heavy and light chains of human monoclonal lupus autoantibodies containing the dominant 16/6 idiotype. , 1985, The Journal of clinical investigation.

[5]  M. Lifely,et al.  Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide , 1985, Infection and immunity.

[6]  K. Timmis,et al.  NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Bach,et al.  Binding of a monoclonal anti-DNA autoantibody to identical protein(s) present at the surface of several human cell types involved in lupus pathogenesis. , 1985, The Journal of clinical investigation.

[8]  J. G. Vinter,et al.  Conformational and dynamic differences between N. meningitidis serogroup B and C polysaccharides, using n.m.r. spectroscopy and molecular mechanics calculations. , 1984, Carbohydrate research.

[9]  B. Diamond,et al.  Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Rudikoff,et al.  Monoclonal antibodies to DNA and RNA from NZB/NZW F1 mice: antigenic specificities and NH2 terminal amino acid sequences. , 1984, Journal of immunology.

[11]  G. Larson,et al.  The Escherichia coli K1 capsule shares antigenic determinants with the human gangliosides GM3 and GD3. , 1984, The New England journal of medicine.

[12]  L. van de Putte,et al.  Cross-reactivity of anti-DNA antibodies with proteoglycans. , 1984, Clinical and experimental immunology.

[13]  M. Heidelberger.  Precipitating cross-reactions among pneumococcal types , 1983, Infection and immunity.

[14]  D. Isenberg,et al.  Idiotypic cross-reactions of monoclonal human lupus autoantibodies , 1983, The Journal of experimental medicine.

[15]  M. Leinonen,et al.  ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis , 1983, The Lancet.

[16]  D. Brown,et al.  Immunological properties of monoclonal antibodies specific for meningococcal polysaccharides: the protective capacity of IgM antibodies specific for polysaccharide group B. , 1983, Journal of general microbiology.

[17]  R. Schwartz,et al.  Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. , 1983, The New England journal of medicine.

[18]  R. Schneerson,et al.  Identification of immunoglobulin heavy-chain isotypes of specific antibodies of horse 46 group B meningococcal antiserum , 1982, Journal of clinical microbiology.

[19]  R. Schwartz,et al.  Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids , 1981, The Journal of experimental medicine.

[20]  L. Chess,et al.  FUNCTIONAL ANALYSIS OF HUMAN T CELL SUBSETS DEFINED BY MONOCLONAL ANTIBODIES , 1981 .

[21]  E. Kabat,et al.  Human monoclonal macroglobulins with specificity for Klebsiella K polysaccharides that contain 3,4-pyruvylated-D-galactose and 4,6- pyruvylated-D-galactose , 1980, The Journal of experimental medicine.

[22]  K. Nelson,et al.  Community-acquired purulent meningitis: a review of 1,316 cases during the antibiotic era, 1954-1976. , 1980, Reviews of infectious diseases.

[23]  P. Ferrier,et al.  Protection against Escherichia coli K1 infection in newborn rats by antibody to K1 capsular polysaccharide antigen , 1980, Infection and immunity.

[24]  E. Kabat.  Basic principles of Antigen-Antibody Reactions. , 1980, Methods in enzymology.

[25]  J. Griffiss,et al.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. , 1979, The Journal of clinical investigation.

[26]  A. Sutton,et al.  Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide , 1979, The Journal of experimental medicine.

[27]  J. Pitt.  K-1 Antigen of Escherichia coli: Epidemiology and Serum Sensitivity of Pathogenic Strains , 1979, Infection and immunity.

[28]  L. Young,et al.  Phagocytic resistance of Escherichia coli K-1 isolates and relationship to virulence , 1978, Journal of clinical microbiology.

[29]  E. Moxon,et al.  Pathogenesis of neonatal Escherichia coli meningitis: induction of bacteremia and meningitis in infant rats fed E. coli K1 , 1977, Infection and immunity.

[30]  G. Mccracken,et al.  Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. , 1974, The New England journal of medicine.

[31]  J. Brouet,et al.  Antibody activity of human myeloma globulins. , 1973, Seminars in hematology.

[32]  D. Kasper,et al.  Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. , 1973, Journal of immunology.

[33]  Kabat and Mayer's Experimental Immunochemistry , 1962 .

[34]  E. Kabat,et al.  Immunochemical Studies on Blood Groups.1 XXVII. Periodate Oxidation of Blood Group A, B and O(H) Substances , 1962 .

[35]  J. Marrack.  Kabat and Mayer's Experimental Immunochemistry (2nd Edition) , 1961 .

[36]  G. T. Barry.  COLOMINIC ACID, A POLYMER OF N-ACETYLNEURAMINIC ACID , 1958, The Journal of experimental medicine.

[37]  O. Ouchterlony,et al.  Antigen-antibody reactions in gels. IV. Types of reactions in coordinated systems of diffusion. , 2009, Acta pathologica et microbiologica Scandinavica.

[38]  K. D. Blackfan.  THE TREATMENT OF MENINGOCOCCUS MENINGITIS , 1922 .